Moreover, after oGTT neither peak nor total GIP concentrations differed significantly between patients and controls (Table 2; Figure 2A) or NAFLD and NASH subgroups (Table 3; Figure 2B). The gene discussed is GIP; the disease is metabolic dysfunction-associated steatohepatitis.